Program
KP-001
A development code.
Its studies are mostly in Lymphatic Abnormalities, led by Kaken Pharmaceutical.
Furthest: phase 3, since Nov 19, 20253 company-led studies, 1 open or runningNext primary completion: Feb 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kaken Pharmaceutical | 31 open or running | phase 3since Nov 19, 2025 | Sep 12, 2024 | Feb 2028phase 3 · NCT07285005 |
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2024First studies: 2 phase 1 studiesFirst studyNCT06619054, NCT06649942
- Nov 19, 2025Phase 3 study in Lymphatic AbnormalitiesPhase 3 reachedNCT07285005 · 150 planned · United States, South Korea, Taiwan
Ahead
- Feb 2028Primary completion: phase 3 study in Lymphatic AbnormalitiesNCT07285005
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07285005Lymphatic Abnormalities · United States, South Korea, Taiwan | 3 | Recruiting | Feb 2028 | 150 |
| NCT06649942Healthy Volunteers - Male and Female · United States | 1 | Completed | Mar 24, 2025 | 40 |
| NCT06619054Healthy Adults · United States | 1 | Completed | May 16, 2025 | 24 |
How it is read
Names in the registry
- “KP-001”, 4 entries
Codes read as this program: KP001.
Conditions, from the studies’ own filings
- Lymphatic Abnormalities, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.